![Masaaki Hirano](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Masaaki Hirano
Directeur/Membre du Conseil chez OCATA THERAPEUTICS INC
Postes actifs de Masaaki Hirano
Sociétés | Poste | Début | Fin |
---|---|---|---|
OCATA THERAPEUTICS INC | Directeur/Membre du Conseil | - | - |
Historique de carrière de Masaaki Hirano
Anciens postes connus de Masaaki Hirano
Sociétés | Poste | Début | Fin |
---|---|---|---|
AUDENTES THERAPEUTICS, INC. | Directeur/Membre du Conseil | 15/01/2020 | - |
Astellas Pharma Europe Ltd.
![]() Astellas Pharma Europe Ltd. Pharmaceuticals: MajorHealth Technology Astellas Pharma Europe Ltd. engages in the development and sale of pharmaceutical products. The company is headquartered in Addlestone, the United Kingdom. | Directeur/Membre du Conseil | 01/04/2018 | - |
Statistiques
Internationale
Etats-Unis | 3 |
Royaume-Uni | 2 |
Opérationnelle
Director/Board Member | 3 |
Sectorielle
Health Technology | 4 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
Entreprise privées | 3 |
---|---|
Astellas Pharma Europe Ltd.
![]() Astellas Pharma Europe Ltd. Pharmaceuticals: MajorHealth Technology Astellas Pharma Europe Ltd. engages in the development and sale of pharmaceutical products. The company is headquartered in Addlestone, the United Kingdom. | Health Technology |
Astellas Gene Therapies, Inc.
![]() Astellas Gene Therapies, Inc. BiotechnologyHealth Technology Astellas Gene Therapies, Inc. is a biotechnology company, which engages in the development and commercialization of gene therapy products for patients with serious and rare diseases caused by single gene defects. The company was founded by Matthew R. Patterson and Thomas J. Schuetz on November 13, 2012 and is headquartered in San Francisco, CA. | Health Technology |
Astellas Institute for Regenerative Medicine
![]() Astellas Institute for Regenerative Medicine Pharmaceuticals: MajorHealth Technology Astellas Institute for Regenerative Medicine engages in the development and commercialization of human pluripotent stem cell technology in the field of regenerative medicine. The company also have a preclinical development pipeline in areas outside of ophthalmology, including; autoimmune diseases, inflammatory diseases, and wound healing. The company was founded on May 18, 2000 and is headquartered in Marlborough, MA. | Health Technology |
- Bourse
- Insiders
- Masaaki Hirano
- Expérience